Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Patients With Borderline Resectable Pancreatic Cancer
Interventions
DRUG

FIRINOX

FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.

Trial Locations (9)

Unknown

Nagoya University, Nagoya

Kobe University, Kobe

Nara Prefectual Medical University, Kashihara

Kansai Medical University, Hirakata

Osaka University, Suita

Hiroshima University, Hiroshima

Osaka City University, Osaka

Osaka Medical Center for Cancer and CVD, Osaka

641-8510

Wakayama Medical University, Wakayama

All Listed Sponsors
lead

Wakayama Medical University

OTHER

NCT02148549 - Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study | Biotech Hunter | Biotech Hunter